



PTO/SB/08B (08-00)

Approved for use through 10/31/2002 OMB 0651-0031

U. S. Patent and Trademark Office U. S. DEPARTMENT OF COMMERCE

Please type a plus sign (+) inside this box → +

Under the Paperwork Reduction Act of 1995, no person is required to respond to the collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet

2

PATENT & TRADEMARK OFFICE

Complete if Known

Application Number	09/966,781
Filing Date	September 28, 2001
First Named Inventor	Patricia Soulard
Group Art Unit	1645 1652
Examiner Name	R. AMIREZ
Attorney Docket Number	A0000281-66-MG

FEB 05 2002

RECEIVED

OTHER PRIOR ART – NON PATENT LITERATURE DOCUMENTS

Examiner Initials	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
DR		J.A. BEAVO, Physiol. Rev., 1995, pp 725-748, Vol. 75	
		T.L. FINK, et al., "Expression of an Active, Monomeric Catalytic Domain of the cGMP-binding cGMP-specific Phosphodiesterase (PDE5)", J. Biol. Chem., 12/3/1999, pp 34,613-34,620, Vol. 274, No. 49	
		J LIM, et al., " Activation of the cAMP-specific Phosphodiesterase PDE4D3 by Phosphorylation" J. Biol. Chem., 7/9/1999, pp 29677-19685, Vol. 274, No. 28	
		S.L.C. JIN, et al. "Characterization of the Structure of a Low Km, Rolipram-sensitive cAMP Phosphodiesterase", J. Biol. Chem., 9/15/1992, pp 18929-18939, Vol. 267, No. 26	
		T. KOVALA, et al., "Recombinant Expression of a Type IV, cAMP-Specific Phosphodiesterase: Characterization and Structure-Function Studies of Deletion Mutants", Biochem., 1997, pp 2968-2976, Vol. 36	
		T. MICHAELI, et al., "Isolation and Characterization of a Previously Undetected Human cAMP Phosphodiesterase by Complementation of cAMP Phosphodiesterase-deficient Saccharomyces cerevisiae", J. Biol. Chem., 6/15/1993, pp 12925-12932, Vol. 268, No. 17	
		W.K. SONNENBURG, et al., "Identification of Inhibitory and Calmodulin-binding Domains of the PDE1A1 and PDE1A2 Calmodulin-stimulated Cyclic Nucleotide Phosphodiesterases", J. Biol. Chem., 12/29/1995, pp 30989-31000, Vol. 270, No. 52	
		Y. KENAN, et al., "Functions of the N-terminal Region of Cyclic Nucleotide Phosphodiesterase 3 (PDE 3) Isoforms", J. Biol. Chem., 4/21/2000, pp 12331-12338, Vol. 275, No. 16	
		WOLFGANG BAEHIR, et al. "Isolation and Characterization of cGMP Phosphodiesterase from Bovine Rod Outer Segments", J. Biol. Chem., 11/25/1979, pp 11669-11677, Vol. 254, No. 22	
		J. A. BEAVO, et al., "Hydrolysis of Cyclic Guanosine and Adenosine 3',5'-Monophosphates by Rat and Bovine Tissues", J. Biol. Chem., 11/10/1970, pp 5649-5655, Vol. 245, No. 21	
DR	1	TIMOTHY J. BLOOM, et al., " Identification and Tissue-specific Expression of PDE7 Phosphodiesterase Splice Variants", Proc. Natl. Acad. Sci. USA, 11/1996, pp 14188-14192, Vol. 93	

Examiner Signature

Date Considered

6/4/04

¹EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

² Unique citation designation number. ³ Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U. S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

RECEIVED
TECH CENTER 1600/2900
JUN 8 05 2002

Please type a plus sign (+) inside this box → +

JAN 16 2002

PTO/SB/08B (08-00)

Approved for use through 10/31/2002 OMB 0651-0031

U. S. Patent and Trademark Office U. S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no person is required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO

Complete if Known

INFORMATION DISCLOSURE
STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet

3

of

3

Application Number

09,966,781

Filing Date

September 28, 2001

First Named Inventor

Patricia Soulard

Group Art Unit

1645 1652

Examiner Name

RAMIREZ

Attorney Docket Number

A0000281-66-MG

OTHER PRIOR ART – NON PATENT LITERATURE DOCUMENTS

Examiner Initials ¹	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
		BERNARD K. K. FUNG, et al., "Subunit Stoichiometry of Retinal Rod cGMP Phosphodiesterase". Biochem., 1990, pp 2657-2664, Vol. 29	
DR		CLARE GARDNER, et al., "Cloning and Characterization of the Human and Mouse PDE7B, a Novel cAMP-Specific Cyclic Nucleotide Phosphodiesterase", Biochem. Biophys. Res. Commun., 2000, pp 186-192, Vol. 272	
DR		PING HAN, et al., "Alternative Splicing of the High Affinity cAMP-Specific Phosphodiesterase (PDE7A) mRNA in Human Skeletal Muscle and Heart", J. Biol. Chem., 6/27/1997, pp 16152-16157, Vol. 272, No. 26	
DR		RALF HOFFMANN, et al., "Differential Distribution of Rat PDE-7 mRNA in Embryonic and Adult Rat Brain", Cell Biochem. Biophys., 1998, pp 103-113, Vol. 28	
DR		MICHIO ICHIMURA, et al., "A new Cyclic Nucleotide Phosphodiesterase Isozyme Expressed in the T-Lymphocyte Cell Lines", Biochem. Biophys. Res Commun., 6/30/1993, Vol. 193, No. 3	
DR		CAROLYN J. SMITH, et al., "Hormone-sensitive Cyclic GMP-inhibited Cyclic AMP Phosphodiesterase in Rat Adipocytes", J. Biol. Chem., 7/15/1991, pp 13385-13390, Vol. 266, No. 20	
DR		THEODORE J. TORPHY, et al., "Biochemical Characteristics and Cellular Regulation of Phosphodiesterase IV", New Drugs in Allergy and Asthma, 1993, pp 51-71, Agents & Actions Supplement Vol. 43	
DR		Genbank Accession No: U77880; Rattus norvegicus GI:1916748; 9/28/2001	
DR		Genbank Accession No: AJ251860 Homo sapiens mRNA GI:8216982; 5/24/2000	
DR		Genbank Accession No: L12052 Homo sapiens cAMP GI:179892; 7/22/1999	
DR		Genbank Accession No: U68171 Mus musculus cycl GI:1549394; 9/18/1996	
DR	1	Genbank Accession No: U67932 Homo sapiens cAMP GI:2306763; 7/22/1999	

Examiner Signature

Date Considered

6/4/04

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U. S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.